— Know what they know.
Not Investment Advice
Also trades as: 2137.HK (HKSE) · $vol 0M

BRIBF OTC

Brii Biosciences Limited
1W: +0.0% 1M: +0.0% 3M: -13.0% YTD: -30.4% 1Y: -46.0% 3Y: -89.6%
$0.13
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 43 · $93.8M mcap · 563M float · 0.0005% daily turnover · Short 84% of daily vol

Cash Flow Trends

Operating Cash Flow
-$373M +37.2% ▲
Capital Expenditures
$3M +93.5% ▲
5Y CAGR: -33.1%
Free Cash Flow
-$376M +41.6% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$220K +81.1% ▲
Net Change in Cash
$514M +173.3% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income-$1.3B-$4.2B-$490M-$184M-$512M
Depreciation & Amort.$14M$17M$17M$16M$9M
Stock-Based Comp.$29M$79M$78M$64M$16M
Change in Working Capital$471M-$334M-$77M-$121M-$50M
Other Non-Cash Items$350M$3.6B-$24M-$369M$165M
Operating Cash Flow-$404M-$879M-$496M-$594M-$373M
— Investing Activities —
Capital Expenditures$0-$1M-$139M$0-$3M
Acquisitions (Net)$0$2M$0$0$0
Investment Purchases-$196M-$500M-$2.1B-$3.5B-$1.9B
Investment Sales$154M$20M$775M$3.3B$2.8B
Other Investing-$1M$3M$33M$115M-$6M
Investing Cash Flow-$44M-$476M-$1.4B-$104M$895M
— Financing Activities —
Net Debt Issuance-$7M-$10M-$9M-$10M-$7M
Stock Repurchased$0$0-$678K-$1M-$220K
Dividends Paid$0$0$0$0$0
Other Financing-$5M-$88M$7M-$315K-$2M
Financing Cash Flow$657M$3.2B-$3M-$11M-$9M
Net Change in Cash$155M$1.8B-$1.7B-$701M$514M
Cash End of Period$1.0B$2.9B$1.2B$490M$1.0B
Free Cash Flow-$404M-$880M-$636M-$644M-$376M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms